Yes, targeting cyclin D and its associated kinases (CDK4/6) is a promising therapeutic approach. CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, have been developed and approved for the treatment of hormone receptor-positive, HER2-negative breast cancer. These inhibitors work by blocking the activity of CDK4/6, thereby preventing cyclin D-mediated cell cycle progression and inducing cell cycle arrest.
